| Is There a Clinically Significant Interaction Between Calcium Channel Antagonists and Clopidogrel?: Results From the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial. | |
| | |
MedLine Citation:
|
PMID: 22319066 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: Clopidogrel is an inactive prodrug; it is converted to its active metabolite through the cytochrome P450 (CYP3A4) pathway, which also metabolizes calcium channel blockers (CCBs). Several studies have reported that CCBs reduce the ability of clopidogrel to inhibit platelet aggregability; one suggested that CCBs reduce the efficacy of clopidogrel. METHODS AND RESULTS: We performed a post hoc analysis of the Clopidogrel for the Reduction of Events During Observation (CREDO) study to compare the treatment effect of clopidogrel in patients on CCBs versus not on CCBs. In CREDO, 2116 patients were randomly assigned to pretreatment with 300 mg clopidogrel 3-24 hours before a planned percutaneous coronary intervention followed by 1 year of 75 mg/d clopidogrel, versus 75 mg clopidogrel at the time of the procedure and continued for 28 days only. The primary end points were a combined end point of death, myocardial infarction, and stroke at 28 days and 1 year. Among the 580 patients (27%) on CCBs at enrollment, at 28 days, the combined end point was reached in 17 patients (6%) on clopidogrel versus 28 (9%) on placebo (hazard ratio [HR], 0.71; 95% confidence interval [CI], 0.39-1.29). At 1 year, the combined end point was reached in 27 patients (10%) on clopidogrel versus 46 (15%) on placebo (HR, 0.68; 95% CI, 0.42-1.09). The treatment effect of clopidogrel was similar in patients not on CCBs at 1 year (HR, 0.78; 95% CI, 0.56-1.09). After adjustment for differences between patients on and not on CCB, there was still no evidence of an interaction between clopidogrel treatment and CCB (HR for patients not on CCBs, 0.87; 95% CI, 0.62-1.23; HR for patients on CCBs, 0.74; 95% CI, 0.45-1.21). CONCLUSIONS: In CREDO, there was no evidence that CCBs decrease the efficacy of clopidogrel. |
| | |
Authors:
|
Christopher W Good; Steven R Steinhubl; Danielle M Brennan; A Michael Lincoff; Eric J Topol; Peter B Berger |
Related Documents
:
|
22403276 - Efficacy and tolerance of urea compared with vaptans for long-term treatment of patient... 22769236 - Safety and efficacy outcomes of long-term treatment up to 4 years with 5% lidocaine med... 9217566 - Nonadherence in tuberculosis treatment: predictors and consequences in new york city. 22460966 - Long-term valacyclovir suppressive treatment after herpes simplex virus type 2 meningit... 10719806 - Outcome of adults with repaired tetralogy of fallot. 12377866 - Grading the severity of obstruction in the presence of a restrictive ventilatory defect. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-2-7 |
Journal Detail:
|
Title: Circulation. Cardiovascular interventions Volume: - ISSN: 1941-7632 ISO Abbreviation: - Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-2-9 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101499602 Medline TA: Circ Cardiovasc Interv Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Geisinger Clinic, Danville, PA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Percutaneous femoral arteriovenous shunt creation for advanced chronic obstructive pulmonary disease...
Next Document: Long-Term Clinical Outcome After Fractional Flow Reserve-Guided Percutaneous Coronary Revascularizat...